Literature DB >> 24401641

Antiretroviral reduction: is it time to rethink the unthinkable?

Jonathan Colasanti1, Vincent C Marconi, Babafemi Taiwo.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24401641     DOI： 10.1097/QAD.0000000000000187

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  3 in total

1.  Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database.

Authors:  Gaetana Sterrantino; Mauro Zaccarelli; Antonio Di Biagio; Maria Luisa Biondi; Andrea Antinori; Giovanni Penco
Journal:  Infection       Date:  2015-03-28       Impact factor: 3.553

2.  Individualized Protease Inhibitor Monotherapy: The Role of Pharmacokinetics and Pharmacogenetics in an Aged and Heavily Treated HIV-Infected Patient.

Authors:  Elena López Aspiroz; Salvador Enrique Cabrera Figueroa; María Paz Valverde Merino; Ángel Carracedo Álvarez
Journal:  Clin Drug Investig       Date:  2019-11       Impact factor: 2.859

3.  Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients.

Authors:  Camelia Gubavu; Thierry Prazuck; Mohamadou Niang; Jennifer Buret; Catherine Mille; Jérôme Guinard; Véronique Avettand-Fènoël; Laurent Hocqueloux
Journal:  J Antimicrob Chemother       Date:  2015-12-27       Impact factor: 5.790
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.